Interview with Dr James Garner, CEO of Kazia Therapeutics

XR-17 is Vivesto’s proprietary delivery platform

Vivesto published its Q2 report for 2022 on August 25, 2022, at 08.00 am CEST. The company will hold a conference call and an online presentation on the same day at 10.00 am CEST.

The Share

Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program

Annual Report 2021